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Summary Nasal problems are frequent at high continuous positive airway pressure
(CPAP). We hypothesized that a reduction of the nasal resistance reduces CPAP and
investigated the effect of a nasal valve dilator (Nozovents) on CPAP in patients with
obstructive sleep apnea. In a randomized cross-over design Nozovents was inserted
in 38 patients during one of two nights using AutoSet Ts. CPAP differences41 cm H2O
were considered as clinically relevant. With Nozovents the median CPAP pressure
was reduced from 8.6 cm H2O to 8.0 H2O (P ¼ 0:023) in all patients, but the number of
patients with a reduction of CPAP by 1 cm H2O was not significant. The median CPAP
level among 20 patients requiring a CPAP level of above 9 cm H2O was reduced from
10.3 to 9.1 cm H2O, Po0:05: A clinical improvement with Nozovents was seen in 10 of
20 patients requiring a pressure of above 9 cm H2O compared with 4 of 18 patients
who needed lower pressures, P ¼ 0:025: Nozovents reduces the CPAP level 1 cm H2O
in 50% of patients requiring a high pressure (49 cm H2O). Future studies should
identify possible patients benefiting from a nasal dilator during CPAP therapy.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Nasal dryness, nasal congestion and drippy nose
occur in about 50% of patients treated with
continuous positive airway pressure (CPAP) because
of obstructive sleep apnea (OSA).1–3 These nasal
problems are a main side effect of CPAP and also a
main reason for discontinuing CPAP therapy.4
Mesiler et al.3 observed that a dry mouth and a
drippy nose were more frequent at pressure levels
of above 12 cm H2O than below 8 cm H2O. Dis-
turbances from a noisy blower was another main
complaint.2,3
Several nasal dilating devices, including the nasal
valve dilator (Nozovents), reduce nasal resistance
and improve nasal breathing.5,6 The Nozovents
consists of a plastic bar that dilates the anterior
part of the nose, the valve region, in order to
increase airflow. Nozovents lacks effect on snoring
and sleep apnea,6,7 but it reduces nasal resistance
and increases airflow. A consequent treatment of
nasal obstruction might reduce nasal side effects
during CPAP therapy and hence improve compliance
with CPAP. In this study we aimed to investigate
whether Nozovents would lower the CPAP level
required to abolish sleep apneas. We therefore
investigated the effect of a plastic nasal valve
dilator (Nozovents) during CPAP treatment. We
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applied a validated CPAP autotitration device
(AutoSet Ts),8 in order to provide a more repro-
ducible procedure to find the adequate CPAP level
compared to traditional CPAP titration.
Materials and methods
Patients
The population consisted of subjects referred to
the Krankenhaus Kloster Grafschaft for assessment
of possible sleep disordered breathing. Thirty-eight
consecutive patients with respiratory disturbances
index over 20 events/h, according to simplified
ambulatory sleep apnea recordings and a history of
snoring were included. They were 31 men and 7
women with a mean age of 55.4711.4 years old. All
subjects were tired during the daytime with
an Epworth sleepiness scale score over 10.
An informed consent was obtained from each
participating subject.
The nasal dilator
The nasal dilator (Nozovents, Prevancure AB,
Sweden, Fig. 1) consists of a plastic bar with two
tabs on each end. It is designed to fit inside the
nostril and dilate the nasal valves by means of its
elasticity and thus decrease nasal resistance and
improve airflow. Each patient was given the optimal
size of the device (i.e. small, medium or large).
Patients with reduced tolerance were instructed to
apply the device at least two times a day in order to
familiarize with the treatment.
Study design
The nasal dilators (Nozovents) were inserted with
a randomized cross-over design during one of two
CPAP titration nights. Median, 95% percentile and
maximum of CPAP pressure during the CPAP titra-
tion nights were analyzed using AutoSet Ts auto-
matic CPAP system (ResMed, M .onchengladbach,
Germany) which eliminates detected airflow lim-
itations by increasing CPAP pressure. In all patients
the upper and lower limits of CPAP pressure levels
were kept stable for both nights at a minimum of
4 cm H2O and at a maximum of 16 cm H2O. The
stabilization time for reacting on detected events
by increasing CPAP pressure was set to 1min.
Pressure differences of 1 cm H2O or more were
considered clinical relevant.
All patients were given the following question
after each study night: ‘‘Did an intranasal irritation
caused by Nozovent disturb your sleep quality
during the past night?’’ They were asked to answer
‘‘yes’’ and ‘‘no’’ and also to make additional
comments.
Polygraphic recordings
Standard polygraphic recordings were made using
PolyMESAM (MAP, Martinsried, Germany) and stan-
dard polysomnographic recordings were done with
the MAP-LABs system (MAP, Martinsried, Germany).
Respiration was monitored using oro-nasal thermis-
tors and thoracic and abdominal movements by
piezo belts. Body position and oxygen saturation
(SaO2) using finger oximetry were also recorded. A
microphone was placed immediately below the
larynx. Breathing sounds were analyzed based on
the MESAM 4 algorithm.
Apnea was defined as a complete cessation of
oro-nasal airflow for at least 10 s. Apneas were
classified as obstructive when thoracic or abdom-
inal movements were present. A central apnea was
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Fig. 1 Schematic drawing of Nozovents device.
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scored if a complete cessation of oro-nasal airflow
lasting at least 10 s occurred in the absence of
thoraco-abdominal movements. A hypopnea was
defined as a 50% or larger reduction in the
amplitude of the airflow waveform from a preced-
ing stable baseline, associated with a decrease in
oxygen saturation of 4% or more. Apnea index (AI)
was defined as the number of apneas divided by
hours of sleep and respiratory disturbance index
(RDI) as the mean number of apneas and hypopneas
per hour of sleep. Finally, the mean and nadir
oxygen saturation (SaO2) associated with an
abnormal respiratory event during sleep were
determined.
Statistical analysis
Results were expressed as the mean7standard
deviation (SD). For comparison of pressures, RDI,
AI, SaO2 mean and SaO2 nadir with and without
Nozovents t-tests for dependent samples were
used. For identification of responder-subgroups t-
tests for independent samples (gender) and Pearson
product-moment correlations (age) were used. Chi-
square test was used to test whether the number of
patients with clinical improvement or deterioration
differ. A two-tailed P-value o0.05 was considered
significant.
Results
Thirty-eight patients (31 males, 7 females) with a
mean body mass index of 35.375.6 kg/m2, a mean
age of 55.4711.4 years, a mean RDI of 47.2722.9/
h and a mean AI of 17.1718.3/h were included in
the study. Using Nozovents, the median CPAP
pressure in the whole population was reduced from
a mean (SD) of 8.6 (72.2) to 8.0 (72.2) cm H2O
(P ¼ 0:023). Mean 95% percentile of CPAP pressure
and maximum CPAP pressure during the night were
unaffected by the use of Nozovents (Table 1). The
median CPAP pressure with Nozovents remained
within71 cm H2O in 18 patients compared to CPAP
Pressure without Nozovents. We found no differ-
ence in the number of patients with clinical
improvement (i.e. CPAP pressure decreased in 14
patients) or deterioration (i.e. CPAP pressure
increased in six patients) (P40:05).
Taking 9 cm H2O as a threshold value 20 of 38
patients required a median pressure of above 9 cm
H2O without Nozovent (Group 1) (Fig. 2). The mean
median pressure was reduced from 10.3 (71.0) to
9.1 (71.6) cm H2O, Po0:05 among them. Eighteen
of 38 patients required a median pressure of 9 cm
H2O or less without Nozovent (Group 2). They had a
mean median pressure of 6.7 (71.4) without
Nozovents and 6.8 (72.1) cm H2O with Nozovent
s
(P40:05).
A clinical improvement, i.e. with a reduction of
CPAP pressure more than 1 cm H2O, using Nozovent
s
was seen more often in group 1 to compared group
2 (P ¼ 0:025). The median pressure was reduced by
41 cm H2O in 50% (10 of 20 patients) in group 1, in
nine patients the resulting difference was o1 cm
H2O and in one patient it increased by exactly 1 cm
H2O using Nozovent
s. In contrast to that, in group
2 only 4 of 18 patients reduced the pressure more
than 1 cm H2O, seven patients increased the
pressure 41 cm H2O and seven patients had a
difference of o1 cm H2O between the two record-
ings.
There were no gender differences regarding the
effect of Nozovents on CPAP level or polygraphic
data and no correlation with age was observed. The
responder group (41 cm H2O decrease of median
CPAP level) did not differ from non-responders
regarding BMI, RDI or AI (P40:3).
RDI and AI decreased and SaO2 values increased
significantly during CPAP therapy (Po0.001) but
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Table 1 CPAP pressure with and without nasal
dilator.
Pressure (cm
H2O)
Without
Nozovent
With
Nozovent
P-value
Median 8.672.2 8.072.2 0.0231
95%-
Percentile
10.872.0 10.672.3 0.4637
Maximum 12.0 7 2.1 11.972.4 0.5281
CPAP > 9 cm H2O
CP
AP
 [c
m 
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O
]
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14
without Nozovent with Nozovent without Nozovent with Nozovent
CPAP <= 9 cm H2O
Fig. 2 Median CPAP without and with Nozovents in
the two groups with CPAPo or 49 cm H2O without
Nozovents.
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these indices were not influenced from the nasal
dilator (P40:05; Table 2). Polygraphic data at
baseline and during CPAP titration with and without
Nozovents are given in Fig. 3.
Finally, no patient indicated sleep disturbance
caused by local side effects of Nozovents.
Discussion
Using Nozovents, the required CPAP level was
reduced for the whole group of 38 patients studied,
but the reduction was below 1 cm H2O and there-
fore not regarded as clinically relevant. The
reduction was, however, more prominent among
subjects who required a CPAP of above 9 cm H2O
and 50% of these patients had a clinical relevant
reduction of the median CPAP level of 1 cm H2O or
more using Nozovents. We can however not
exclude that high initial CPAP pressures reduce
more than lower pressures after intervention, i.e. a
‘‘regression towards the mean’’ phenomenon.
Our results support that Nozovents might be of
value in selected patients requiring high CPAP. It is
possible that the nostrils are diminished in size
because of the external pressure on the alae nasi
during high CPAP levels. Subjects with floppy alae
nasi are probably more vulnerable to external
pressures. As the analysis included consecutive
patients referred to the clinic, an even higher
potential benefit of Nozovents in selected patients
may have been masked.
In this context it is a limitation of the study that
no elaborated examination of the nasal anatomy
(e.g. rhinomanometry or the investigation of the
alar status) by an ear–nose–throat specialist was
done. The later possibly delivers deeper pathophy-
siologic insight and predictors of a successful
intervention with Nozovents.
Only a few studies investigate the effect of
reduced constant CPAP levels on treatment com-
pliance. However, recently a long-term follow up
was published investigating patients with OSA and
moderate nasal obstruction (n ¼ 39) who under-
went functional rhinosurgery before CPAP therapy.9
Mean nasal flow increased by 70% (i.e. from 398 to
711ml/s) in the intervention group. Compared to
the control group, after 3 years the mean CPAP
pressure was 1.5 cm H2O lower and the daily use
increased by 0.8 h/day in the interventional group.
These results indicate that a reduced CPAP level
improves compliance, since a negative correlation
between the CPAP level and the daily CPAP use was
observed in both groups.
Recent studies,10–12 report that nasal resistance
has no impact on the pathogenesis of OSA. Thus,
both snoring and sleep apnea are probably caused
by other factors, such as restrictive processes in the
pharyngeal area, rather than increased nasal
resistance at the nasal valves. Metes et al.6 did
not find any effect on snoring, apneas, hypopneas
or oxygen saturation in a small sample of patients,
despite a reduction in nasal resistance. Moreover,
in a recent study we did not find any effect of
Nozovents on OSA.7
Although nasal resistance and Nozovents do not
seem to affect OSA, it is still possible that the
degree of nasal resistance may affect the CPAP
level to abolish apneas. We did not measure the
nasal resistance or the anatomy of the alae nasi,
which are limitations of the present study. It is
therefore not possible from this study to predict
which patients in particular may benefit from nasal
dilator during CPAP therapy.
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Table 2 Polygraphic data at baseline, CPAP1 (without Nozovents) and CPAP2 (with Nozovents).
Parameter Diagnosis Without Nozovent With Nozovent P-value (Nozovent)
RDI (/h) 47.2722.9 11.978.5 12.478.7 0.7673
AI (/h) 17.1718.3 2.872.7 3.473.5 0.2100
SaO2 mean (%) 92.273.1 94.472.3 93.872.8 0.0791
SaO2 nadir (%) 72.9711.6 84.474.9 80.679.3 0.0632
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Fig. 3 RDI and AI before therapy, with and without nasal
dilator.
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In a recent publication, Wiest et al. reported that
manual CPAP titration results in a difference of up
to 3.0 cm H2O between two consecutive CPAP
titrations despite the use of a standardized proto-
col.13 We applied an autotitration system (Auto-
Sets automatic CPAP system) to determine the
effective minimum pressure required to abolish
sleep apneas. AutoSets is based on an automated,
objective method to eliminate inspiratory flow
limitation. Its algorithm yields a significant im-
provement of sleep-disordered breathing and sleep
architecture considering the titration period14 and
maintained at 3 and 8 months.8 This method is
based on a consistent algorithm and therefore
reduces the potential influence of subjectivity
during manual CPAP titrations.
We intended to measure whether a nasal dilator
could lower the CPAP level or not in an unselected
group of patients. Clinical issues, which need a
longer observation period, were not the aim of this
physiologic study. Thus we did not investigate
whether patients experienced a beneficial effect
from Nozovents regarding sleep quality, improved
nasal ventilation, mask leakage and compliance to
CPAP therapy. In the future we suggest studies using
Nozovent in combination with CPAP on patients
with problems from the nose during CPAP therapy.
One could speculate that the addition of a second
device to the CPAP nasal mask would irritate the
patient and disturb sleep. We cannot exclude such
a negative side from our data, since we did not
study sleep stages in this trial. However, none of
our patients reported any sleep complaints or local
side effects caused by Nozovents during the study.
These findings go in line with published data
measuring sleep quality based on subjective and
objective tools in snorers or patients with OSA who
applied Nozovents during sleep.7,15,16 These stu-
dies excluded a specific Nozovent-induced distur-
bance of sleep quality. Finally, the primary aim of
this study was to investigate the influence of
Nozovents on CPAP pressure and not on sleep
quality.
A nasal dilator (Nozovents) reduces the CPAP
level by more than 1 H2O in 50% of patients with
obstructive sleep apnea requiring a high pressure
(49 cm H2O). We suggest future studies to identify
possible patients that may benefit from a nasal
dilator during CPAP therapy.
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